• Time until recovery of walking with aid Optional secondary outcome measures • Time until off ventilation ( for • Time until walking unaided those ventilated) • Time until recovery of walking with aid • Treatment related fluctuation • Time until off ventilation ( for those ventilated) • Death or disability • Treatment-related fluctuation • Death or disability Approximately 10% of patients relapse, which may require a second treatment with Ig. A second dose of IVIg must only be on the advice of and after assessment by a neurologist. Dose Induction - 2 g/kg in 2 to 5 divided doses. Initial therapy for GBS with significant disability and The dosing approach is the same for both progression. indications. Induction dose is unchanged. Aim for minimum dose to maintain optimal functional status. Initial - 2 g/kg in 2 to 5 divided doses. This script regarding using minimal dose was deleted as inappropriate for this condition - Refer to the current product information the dose is standard for all patients ( unless sheet for further information. Refer to the current product information sheet for lean body mass is being used). The aim should be to use the lowest further information. dose possible that achieves the appropriate clinical outcome for each Relapse in GBS with significant disability and patient. progression post IVIg treatment (neurologist review required) As above - standard dosing applies. Initial - 2 g/kg in 2 to 5 divided doses. Refer to the current product information sheet for further information.
• Time until recovery of walking with aid • Time until off ventilation ( for those ventilated) • Treatment related fluctuation • Death or disability Approximately 10% of patients relapse, which may require a second treatment with Ig. A second dose of IVIg must only be on the advice of and after assessment by a neurologist. Optional secondary outcome measures • Time until walking unaided • Time until recovery of walking with aid • Time until off ventilation ( for those ventilated) • Treatment-related fluctuation • Death or disability Dose Induction - 2 g/kg in 2 to 5 divided doses. Aim for minimum dose to maintain optimal functional status. Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Initial therapy for GBS with significant disability and progression. Initial - 2 g/kg in 2 to 5 divided doses. Refer to the current product information sheet for further information. Relapse in GBS with significant disability and progression post IVIg treatment (neurologist review required) Initial - 2 g/kg in 2 to 5 divided doses. Refer to the current product information sheet for further information. The dosing approach is the same for both indications. Induction dose is unchanged. This script regarding using minimal dose was deleted as inappropriate for this condition - the dose is standard for all patients ( unless lean body mass is being used). As above - standard dosing applies.
guillain%E2%80%93barre-syndrome-gbs-including-variants.DOCX